SEC Filing Summary: Graybug Vision, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K reports on the 2022 Annual Meeting of Stockholders held by Graybug Vision, Inc. on June 2, 2022. The filing details the outcomes of three specific proposals submitted to security holders. Note: The input metadata references "Calcimedica, Inc.", but the filing text explicitly identifies the registrant as "Graybug Vision, Inc."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
The following proposals were adopted at the Annual Meeting:
- Election of Directors: Eric Bjerkholt and Frederic Guerard, Pharm.D., were elected as Class II directors for three-year terms expiring in 2025.
- Auditor Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Equity Plan Approval: The Amended and Restated 2020 Equity Incentive Plan was approved.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the correct registrant name is Graybug Vision, Inc., not Calcimedica, Inc.
- Confirm the terms of the newly elected directors (Eric Bjerkholt and Frederic Guerard) expire at the 2025 Annual Meeting.
- Review the specific terms of the Amended and Restated 2020 Equity Incentive Plan approved by shareholders.
- Note the significant number of broker non-votes (5,166,349) on the director election and equity plan proposals.